Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 33

Sort by

Sort Order Select

Journal Articles

Chemotherapy or Stem Cell Transplantation in Adult High Risk Ph/BCR::ABL1-Negative ALL Patients with Early MRD Negativity: Results of the Randomized GMALL Trial 08/2013

Blood (2024) 144 (Supplement 1): 961.

https://doi.org/10.1182/blood-2024-199060

Published: 2024

Journal Articles

Day 30 Mortality in Patients with AML: A Single Center Analysis Based on 1036 Patients

Alena Dalgic, Norbert Gattermann, Ulrich Germing, Sascha Dietrich, Felicitas Schulz, Guido Kobbe, Kathrin Nachtkamp, Sr., Paul Jäger

Blood (2024) 144 (Supplement 1): 1479.

https://doi.org/10.1182/blood-2024-205227

Published: 2024

Journal Articles

CNS Irradiation in Adult De Novo B-Precursor ALL / Lbl: Results of the Randomized GMALL T rial 08/2013 Indicate Potential Antileukemic Efficacy

Blood (2023) 142 (Supplement 1): 828.

https://doi.org/10.1182/blood-2023-179442

Published: 2023

Journal Articles

Validation of a Novel Algorithm with a High Specificity in Ruling out MDS

Felicitas Schulz, Kathrin Nachtkamp, Howard S. Oster, Moshe Mittelman, Norbert Gattermann, Carmen Barthuber, Sarah Schweier, Ulrich Germing

Blood (2022) 140 (Supplement 1): 9789–9790.

https://doi.org/10.1182/blood-2022-163431

Published: 2022

Journal Articles

Inotuzumab Ozogamicin Induction Followed By Standard Chemotherapy Yields High Remission Rates and Promising Survival in Older (>55 Years) Patients with De Novo B-Lymphoblastic Leukemia (GMALL-Initial1 Trial)

Blood (2022) 140 (Supplement 1): 510–512.

https://doi.org/10.1182/blood-2022-162235

Published: 2022

Journal Articles

Comparison of Cytomorphology and Histopathology in Myelodysplastic Syndromes (MDS)

Kathrin Nachtkamp, Corinna Strupp, Rosa Faoro, Norbert Gattermann, Ulrich Germing, Stephan E Baldus

Blood (2022) 140 (Supplement 1): 12345–12346.

https://doi.org/10.1182/blood-2022-166172

Published: 2022

Journal Articles

Results of the Risk-Adapted, MRD-Stratified GMALL Trial 08/2013 in 281 T-ALL / T-Lbl Patients: Excellent Outcome of Standard Risk Thymic T-ALL

Blood (2022) 140 (Supplement 1): 115–117.

https://doi.org/10.1182/blood-2022-158381

Published: 2022

Journal Articles

Expression of CD20 Affects Early MRD Response to Rituximab in Adult B Cell Precursor Lymphoblastic Leukemia of the GMALL 08/2013 Trial

Monika Szczepanowski, Johanna Richter, Miriam Kelm, Heiko Trautmann, Britta Kehden, Matthias Ritgen, Christoph Faul, Kathrin Nachtkamp, Björn Steffen, Andreas Viardot, Johannes Gärtner, Johannes Duell, Claudia D. Baldus, Stefan Schwartz, Nicola Goekbuget, Monika Brüggemann

Blood (2021) 138 (Supplement 1): 2301.

https://doi.org/10.1182/blood-2021-150375

Published: 2021

Journal Articles

Final Induction Therapy Results of an Open Label Phase II Study Using Inotuzumab Ozogamicin for Induction Therapy, Followed By a Conventional Chemotherapy Based Consolidation and Maintenance Therapy in Patients Aged 56 Years and Older with Acute B-Lymphoblastic Leukemia (INITIAL-1 trial)

Blood (2021) 138 (Supplement 1): 2300.

https://doi.org/10.1182/blood-2021-145553

Published: 2021

Journal Articles

Severe Anemia Is Associated with a Risk of Infection in Patients with Myelodysplastic Syndromes

Annika Kasprzak, Julia Andresen, Barbara Hildebrandt, Kathrin Nachtkamp, Andrea Kündgen, Guido Kobbe, Norbert Gattermann, Ulrich Germing

Blood (2021) 138 (Supplement 1): 4668.

https://doi.org/10.1182/blood-2021-151288

Published: 2021

Journal Articles

First Results of the Risk-Adapted, MRD-Stratified GMALL Trial 08/2013 in 705 Adults with Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma (ALL/LBL)

Blood (2021) 138 (Supplement 1): 362.

https://doi.org/10.1182/blood-2021-146306

Published: 2021

Journal Articles

Increased Bone Marrow Iron at Diagnosis Is Associated with Inferior Prognosis in Patients with Myelodysplastic Syndromes

Annika Kasprzak, Sandra Becker, Martina Rudelius, Corinna Strupp, Kathrin Nachtkamp, Judith Strapatsas, Barbara Hildebrandt, Norbert Gattermann, Ulrich Germing

Blood (2021) 138 (Supplement 1): 3700.

https://doi.org/10.1182/blood-2021-152402

Published: 2021

Journal Articles

Combined Retro- and Prospective Analysis of Adherence to Guidelines and Patient-Tailored Therapeutic Recommendations in Patients with Myelodysplastic Syndromes (MDS) at a Tertiary Care Centre

Annika Kasprzak, Kathrin Nachtkamp, MD, Mustafa Kondakci, MD, Thomas Schroeder, MD, Guido Kobbe, MD, Andrea Kündgen, MD, Jennifer Kaivers, MD, Christina Rautenberg, MD, Rainer Haas, MD, Norbert Gattermann, MD, Nicolas Bonadies, MD, Ulrich Germing, MD

Blood (2019) 134 (Supplement_1): 4250.

https://doi.org/10.1182/blood-2019-124512

Published: 2019

Journal Articles

Treatment of MDS, AML and CMML Relapse after Allogeneic Blood Stem Cell Transplantation with Azacitidine, Lenalidomide and Donor Lymphocyte Infusions Results from the Second Interim Analysis of the Prospective Azalena-Trial (NCT02472691)

Thomas Michael Schroeder, MD PhD, Christina Rautenberg, MD, Max Christopeit, Matthias Stelljes, MD, Eva Schmidt, Christoph Groth, MD, Christoph Scheid, MD, Udo Holtick, MD PhD, Stefan A Klein, MD, Dietrich W. Beelen, Kathrin Nachtkamp, MD, Rainer Haas, MD, Ulrich Germing, MD, Nicolaus Kröger, MD, Guido Kobbe

Blood (2018) 132 (Supplement 1): 703.

https://doi.org/10.1182/blood-2018-99-113776

Published: 2018

Journal Articles

Quantitative Next-Generation Sequencing (NGS) Based Monitoring of Minimal Residual Disease (MRD) Predicts Imminent Relapse in Patients with Myeloid Malignancies after Allogeneic Hematopoietic Stem Cell Transplantation

Christina Rautenberg, MD, Beate Betz, Dagmar Wieczorek, Barbara Hildebrandt, Kathrin Nachtkamp, MD, Esther Schuler, Norbert Gattermann, MD, Guido Kobbe, MD, Rainer Haas, MD, Thomas Schroeder, MD

Blood (2017) 130 (Supplement 1): 2005.

https://doi.org/10.1182/blood.V130.Suppl_1.2005.2005

Published: 2017

Journal Articles

Treatment of Relapse of MDS, AML and CMML after Allogeneic Blood Stem Cell Transplantation with Azacitidine, Lenalidomide and Donor Lymphocyte Infusions - Results from the First Interim Analysis of the Azalena-Trial (NCT02472691)

Thomas Schroeder, MD, Christina Rautenberg, MD, Max Christopeit, Matthias Stelljes, MD, Eva Schmidt, Stefan Klein, MD, Christof Scheid, MD, Dietrich W Beelen, MD PhD, Kathrin Nachtkamp, MD, Rainer Haas, MD, Ulrich Germing, MD, Nicolaus Kröger, Guido Kobbe, MD

Blood (2017) 130 (Supplement 1): 4521.

https://doi.org/10.1182/blood.V130.Suppl_1.4521.4521

Published: 2017

Journal Articles

Additional Prognostic Impact of the Percentage of Erythroid Cells in the Bone Marrow of MDS Patients

Judith Neukirchen, MD, Heinz Tuechler, Matteo Giovanni Della Porta, MD, Pierre Fenaux, MD PhD, Ulrich Germing, MD, Agnès Guerci, Kathrin Nachtkamp, MD, Marianna Rossi, MD, Rosa Sapena, Wolfgang R. Sperr, MD, Corinna Strupp, MD, Aspasia Stamatoullas, MD, Peter Valent, MD, John M. Bennett, MD

Blood (2017) 130 (Supplement 1): 4259.

https://doi.org/10.1182/blood.V130.Suppl_1.4259.4259

Published: 2017

Journal Articles

Decitabine As Salvage Therapy for Relapse of AML and MDS after Allogeneic Stem Cell Transplantation - a Retrospective Multicenter Analysis on Behalf of the German Cooperative Transplant Study Group

Thomas Schroeder, MD, Christina Rautenberg, MD, William Hermann Krüger, MD PhD, Uwe Platzbecker, MD, Gesine Bug, MD, Steinmann Juliane, Stefan A. Klein, MD, Olaf Hopfer, Kathrin Nachtkamp, MD, Ariane Dienst, MD, Mustafa Kondakci, MD, Pia Verena Schmidt, MD, Claudia Heyn, MD, Rainer Haas, MD, Ulrich Germing, Martin Bornhäuser, MD, Guido Kobbe, MD

Blood (2016) 128 (22): 3446.

https://doi.org/10.1182/blood.V128.22.3446.3446

Published: 2016

Journal Articles

Comparison Between Wilms' Tumor 1 (WT1) Expression Using a Standardized European Leukemia Net (ELN)-Certified Assay and Other Methods for Detection of Minimal Residual Disease (MRD) in MDS and AML Patients after Allogeneic Blood Stem Cell Transplantation

Christina Rautenberg, MD, Sabrina Pechtel, Barbara Hildebrandt, Beate Betz, Ariane Dienst, MD, Kathrin Nachtkamp, MD, Stefanie Geyh, Pia Verena Schmidt, MD, Claudia Heyn, MD, Mustafa Kondakci, MD, Norbert Gattermann, MD, Rainer Haas, MD, Ulrich Germing, Guido Kobbe, MD, Thomas Schroeder, MD

Blood (2016) 128 (22): 3447.

https://doi.org/10.1182/blood.V128.22.3447.3447

Published: 2016

Journal Articles

Favourable Outcome of Elderly Patients with Multiple Myeloma Treated with Tandem Melphalan 100 High-Dose Therapy, Autologous Stem Cell Transplantation and Novel Agents - a Single Center Experience

Judith Neukirchen, MD, Pia Arat, Charlotte Teutloff, Celina Gerrlich, David Lopez y Niedenhoff, MD, Amelie Boquoi, MD, Ingrida Savickaite, Ariane Dienst, MD, Kathrin Nachtkamp, MD, Norbert Gattermann, MD, Thomas Schroeder, MD, Mustafa Kondakci, MD, Guido Kobbe, MD, Rainer Haas, MD, Roland Fenk, MD

Blood (2016) 128 (22): 3460.

https://doi.org/10.1182/blood.V128.22.3460.3460

Published: 2016

NARROW

Chemotherapy or Stem Cell Transplantation in Adult High Risk Ph/BCR::ABL1-Negative ALL Patients with Early MRD Negativity: Results of the Randomized GMALL Trial 08/2013

Day 30 Mortality in Patients with AML: A Single Center Analysis Based on 1036 Patients

CNS Irradiation in Adult De Novo B-Precursor ALL / Lbl: Results of the Randomized GMALL T rial 08/2013 Indicate Potential Antileukemic Efficacy

Validation of a Novel Algorithm with a High Specificity in Ruling out MDS

Inotuzumab Ozogamicin Induction Followed By Standard Chemotherapy Yields High Remission Rates and Promising Survival in Older (>55 Years) Patients with De Novo B-Lymphoblastic Leukemia (GMALL-Initial1 Trial)

Comparison of Cytomorphology and Histopathology in Myelodysplastic Syndromes (MDS)

Results of the Risk-Adapted, MRD-Stratified GMALL Trial 08/2013 in 281 T-ALL / T-Lbl Patients: Excellent Outcome of Standard Risk Thymic T-ALL

Expression of CD20 Affects Early MRD Response to Rituximab in Adult B Cell Precursor Lymphoblastic Leukemia of the GMALL 08/2013 Trial

Final Induction Therapy Results of an Open Label Phase II Study Using Inotuzumab Ozogamicin for Induction Therapy, Followed By a Conventional Chemotherapy Based Consolidation and Maintenance Therapy in Patients Aged 56 Years and Older with Acute B-Lymphoblastic Leukemia (INITIAL-1 trial)

Severe Anemia Is Associated with a Risk of Infection in Patients with Myelodysplastic Syndromes

First Results of the Risk-Adapted, MRD-Stratified GMALL Trial 08/2013 in 705 Adults with Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma (ALL/LBL)

Increased Bone Marrow Iron at Diagnosis Is Associated with Inferior Prognosis in Patients with Myelodysplastic Syndromes

Combined Retro- and Prospective Analysis of Adherence to Guidelines and Patient-Tailored Therapeutic Recommendations in Patients with Myelodysplastic Syndromes (MDS) at a Tertiary Care Centre

Treatment of MDS, AML and CMML Relapse after Allogeneic Blood Stem Cell Transplantation with Azacitidine, Lenalidomide and Donor Lymphocyte Infusions Results from the Second Interim Analysis of the Prospective Azalena-Trial (NCT02472691)

Quantitative Next-Generation Sequencing (NGS) Based Monitoring of Minimal Residual Disease (MRD) Predicts Imminent Relapse in Patients with Myeloid Malignancies after Allogeneic Hematopoietic Stem Cell Transplantation

Treatment of Relapse of MDS, AML and CMML after Allogeneic Blood Stem Cell Transplantation with Azacitidine, Lenalidomide and Donor Lymphocyte Infusions - Results from the First Interim Analysis of the Azalena-Trial (NCT02472691)

Additional Prognostic Impact of the Percentage of Erythroid Cells in the Bone Marrow of MDS Patients

Decitabine As Salvage Therapy for Relapse of AML and MDS after Allogeneic Stem Cell Transplantation - a Retrospective Multicenter Analysis on Behalf of the German Cooperative Transplant Study Group

Comparison Between Wilms' Tumor 1 (WT1) Expression Using a Standardized European Leukemia Net (ELN)-Certified Assay and Other Methods for Detection of Minimal Residual Disease (MRD) in MDS and AML Patients after Allogeneic Blood Stem Cell Transplantation

Favourable Outcome of Elderly Patients with Multiple Myeloma Treated with Tandem Melphalan 100 High-Dose Therapy, Autologous Stem Cell Transplantation and Novel Agents - a Single Center Experience

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only